From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemagno, Christopher, Cassim, Shamir, Pouyssegur, Jacques, Broisat, Alexis, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312874/
https://www.ncbi.nlm.nih.gov/pubmed/32517181
http://dx.doi.org/10.3390/ijms21114067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312874/
https://www.ncbi.nlm.nih.gov/pubmed/32517181
http://dx.doi.org/10.3390/ijms21114067

Ejemplares similares